Open Label Study Assessing Effectiveness Of Amlodipine/Atorvastatin In Subjects With Hypertension and Dyslipidaemia

An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine -Atorvastatin Combination In Subjects With Hypertension and Dyslipidaemia. (The JEWEL Study)

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00330785

Acronym

JEWEL I

Enrollment

1250

Registered

2006-05-29

Start date

2004-10-31

Completion date

2005-09-30

Last updated

2021-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia, Hypertension

Brief summary

To evaluate the effectiveness of amlodipine/atorvastatin therapy by assessing the percentage of subjects who reach target blood pressure (BP) and LDL-C targets as defined by their governing guidelines.

Interventions

DRUGAmlodipine/Atorvastatin

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients who are above target LDL-C and BP who are eligible for treatment

Exclusion criteria

* High liver enzymes

Design outcomes

Primary

Measure	Time frame
To evaluate the number of patients who reach target blood pressure (BP) and	—
LDL-C targets as defined by their governing guidelines.	—

Secondary

Measure	Time frame
To assess changes from baseline to end of treatment for the following efficacy	—
parameters: LDL-C, total cholesterol (TC), triglycerides, high-density lipoprotein	—
cholesterol (HDL-C), HDL-C/LDL-C ratio, TC/HDL-C ratio. Systolic Blood Pressure	—
(SBP) and Diastolic Blood Pressue (DBP).	—

Countries

Canada, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026